Kinome-wide siRNA screening identifies molecular targets mediating the sensitivity of pancreatic cancer cells to Aurora kinase inhibitors
Lifang Xie(Translational Genomics Research Institute), Haiyong Han(Translational Genomics Research Institute), Qiang Que(Translational Genomics Research Institute), Spyro Mousses(Translational Genomics Research Institute), Jeffrey Kiefer(Translational Genomics Research Institute), Daniel D. Von Hoff(Translational Genomics Research Institute), Yu Zhao(Guangdong University of Technology), Michelle Kassner(Translational Genomics Research Institute), Rubén M. Muñoz(Translational Genomics Research Institute), Hongwei Yin(Agricultural Genomics Institute at Shenzhen)
Cited by 24
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
|Journal of Clinical Oncology|1997|5.9k
A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer
|Annals of Oncology|1996|569
Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients
|Nature Communications|2015|484